Literature DB >> 177070

The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes.

R Felix, R Graham, G Russell, H Fleisch.   

Abstract

Diphosphonates are known to inhibit bone resorption in tissue culture and in experimental animals. This effect may be due to their ability to inhibit the dissolution of hydroxyapatite crystals, but other mechanisms may be important. Since lysosomal enzymes have implicated in the process of bone resorption, we have examined the effect of several phosphonates and of a polyphosphate (P20,2) on lysosomal hydrolases derived from rat liver and rat bone. Dichloromethylene diphosphonate strongly inhibited acid beta-glycerophosphatase (EC 3.1.3.2) and acid p-nitrophenyl phosphatase (EC 3.1.3.2) and to a lesser degree (in descending order) acid pyrophosphatase (EC 3.1.3.-), arylsulfatase A (EC 3.1.6.1), deoxyribonuclease II(EC 3.1.4.6) and phosphoprotein phosphatase (EC 3.1.3.16) of rat liver. Inhibition of acid p-nitrophenyl phosphatase and arylsulfatase A was competitive. Ethane-1-hydroxy-1, 1-diphosphonate did not inhibit any of these enzymes, except at high concentrations. Neither dichloromethylene diphosphonate nor ethane-1-hydroxy-1, 1-diphosphonate had any effect on beta-glucuronidase (EC 3.2.1.31), arylesterase (EC 3.1.1.2) and cathepsin D (EC 3.4.23.5). Of several other phosphonates tested only undec-10-ene-1-hydroxy-1, 1-diphosphonic acid inhibited acid p-nitrophenyl phosphatase strongly, the polyphosphate (P20, I) had little effect. Acid p-nitrophenyl phosphatase in rat calvaria extract behaved in the same way as the liver enzyme and was also strongly inhibited by dichloromethylene diphosphonate, but not by ethane-1-hydroxy-1, 1-diphosphonate. It is suggested that the inhibition of bone resorption by dichloromethylene diphosphonate might be due in part to a direct effect of this diphosphonate on lysosomal hydrolases.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 177070     DOI: 10.1016/0005-2744(76)90291-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Bisphosphonates: mechanisms of action.

Authors:  G A Rodan; H A Fleisch
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

3.  Bisphosphonates inhibit 1,25-dihydroxyvitamin D3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium of rat calvaria in vitro.

Authors:  S A Stronski; L Bettschen-Camin; A Wetterwald; R Felix; U Trechsel; H Fleisch
Journal:  Calcif Tissue Int       Date:  1988-04       Impact factor: 4.333

4.  Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy.

Authors:  S Cascinu; V Casadei; E Del Ferro; P Alessandroni; G Catalano
Journal:  Support Care Cancer       Date:  1996-01       Impact factor: 3.603

5.  Alkaline phosphatase activity does not mediate phosphate transport in the renal-cortical brush-border membrane.

Authors:  H S Tenenhouse; C R Scriver; E J Vizel
Journal:  Biochem J       Date:  1980-08-15       Impact factor: 3.857

6.  Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

7.  Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum.

Authors:  M J Rogers; X Ji; R G Russell; G M Blackburn; M P Williamson; A V Bayless; F H Ebetino; D J Watts
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

8.  Inhibition by aminohydroxypropylidene bisphosphonate (AHPrBP) of 1,25(OH)2 vitamin D3-induced stimulated bone turnover in the mouse.

Authors:  P J Marie; M Hott; M T Garba
Journal:  Calcif Tissue Int       Date:  1985-05       Impact factor: 4.333

Review 9.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

Review 10.  Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment.

Authors:  Lars Rasmusson; Jahan Abtahi
Journal:  Int J Dent       Date:  2014-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.